CD274 and colorectal carcinoma: Results of clinical studies or trials showed that CRC patients with dMMR/MSI-H seem to be relatively more “sensitive” in response to anti-PD-1/PD-L1 mAbs than those CRCs with pMMR/MSI-L: dMMR/MSI-H CRCs treated with anti-PD-1/PD-L1 mAbs exhibit significantly enhanced sustained clinical responses.